HCW Biologics Regained Compliance with Bid Price Rule Per Nasdaq Compliance Letter
Rhea-AI Summary
HCW Biologics (Nasdaq: HCWB) has regained compliance with Nasdaq Listing Rule 5550(a)(2), the Bid Price Rule, following a Nasdaq Hearings Panel decision on June 29, 2026. The company is now compliant with all continued listing requirements and will be subject to a mandatory monitoring period through June 17, 2027.
To support long-term compliance, HCW Biologics plans to effect a one-for-six reverse stock split on June 30, 2026.
Positive
- Regained compliance with Nasdaq Listing Rule 5550(a)(2) Bid Price Rule
- Now compliant with all Nasdaq continued listing requirements
- Nasdaq monitoring period defined through June 17, 2027
- Planned one-for-six reverse stock split to support bid price compliance
Negative
- Mandatory Nasdaq monitoring period extends through June 17, 2027
- One-for-six reverse stock split may reduce number of shares outstanding
News Market Reaction – HCWB
In the Jun 30 session, HCWB declined 5.06%, reflecting a notable negative market reaction. Argus tracked a peak move of +3.4% during that session. Argus tracked a trough of -21.7% from its starting point during tracking. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 26 | Reverse split announcement | Negative | -8.0% | Announced 1-for-6 reverse split to support Nasdaq bid-price compliance. |
| Jun 16 | Phase 1 data | Positive | -6.6% | Reported encouraging early alopecia areata data with favorable safety profile. |
| May 27 | Asset rights regained | Positive | -25.9% | Exercised option to regain full rights to two CAR-T reagents. |
| May 21 | Private placement | Neutral | +6.2% | Priced ~$4M private placement units with accompanying common stock warrants. |
| May 14 | Q1 2026 earnings | Positive | +262.0% | Reported profitable quarter with licensing revenue and highlighted clinical progress. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent HCWB news often saw selling even on seemingly favorable clinical and strategic updates.
Key Terms
listing rule 5550(a)(2) regulatory
nasdaq hearings panel regulatory
reverse stock split financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
Company now compliant with all continued listing rules for Nasdaq
MIRAMAR, Fla., June 30, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (Nasdaq: HCWB), a U.S.-based clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation, focusing on autoimmune disorders and other inflammatory diseases, cancer and senescence-associated dysplasia, today reported that, on June 29, 2026, the Nasdaq Hearings Panel (the “Panel”) of The Nasdaq Stock Market LLC (“Nasdaq” or the “Exchange”) found that the Company regained compliance with Listing Rule 5550(a)(2), the “Bid Price Rule,” per the terms set forth in the Panel’s decision letter dated May 29, 2026, as amended, and is subject to a mandatory monitoring period through June 17, 2027.
To ensure long-term compliance with the Bid Price Rule, the Company will effect a reverse stock split at a one-for-six ratio on June 30, 2026.
About HCW Biologics:
HCW Biologics Inc. (the “Company”) (NASDAQ: HCWB) is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to treat diseases promoted by chronic inflammation, including autoimmune diseases, cancer, and senescence-associated dysplasia. The Company’s immunotherapeutics represent a new class of drugs that it believes have the potential to fundamentally change the treatment of proinflammatory and senescence-associated diseases and conditions that are promoted by chronic inflammation —and in doing so, improve patients’ quality of life and possibly extend longevity. A key aspect of the Company’s clinical development and financing strategy is to focus on its business development programs. See the Company Pipeline at https://hcwbiologics.com/pipeline/
Forward-Looking Statements:
This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, statements relating to the timing, consummation, and impact of the reverse stock split, the Company’s ability to maintain long-term compliance with Nasdaq’s minimum bid price requirement, and the actions of third parties, including Equiniti, the Company’s transfer agent, with respect to the reverse stock split. Actual results could differ from those projected in any forward-looking statement due to numerous factors. Such factors include, among others, our ability to maintain compliance with Nasdaq’s continued listing rules. These forward-looking statements are made as of the date of this press release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents we file with the Securities and Exchange Commission, or the SEC, available at www.sec.gov, including, without limitation, the Company’s most recent Annual Report on Form 10-K filed on March 31, 2026, and other SEC filings.
Company Contact:
Rebecca Byam
CFO
HCW Biologics Inc.
rebeccabyam@hcwbiologics.com
